Thursday, October 8, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 22, 2026

D-Wave Quantum (QBTS) Q3 2024 Earnings Transcript

View original at finance.yahoo.com
D-Wave Quantum (QBTS) Q3 2024 Earnings Transcript Image source: The Motley Fool. Date Thursday, November 14, 2024 at 8 a.m. ET Call participants Chief Executive Officer — Alan Baratz Chief Financial Officer — John Markovich Need a quote from a Motley Fool analyst?…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • D-Wave's intellectual property covers both annealing AND gate model technologies, with majority of 240+ US granted patents covering both

    80% confidence
  • Q4 revenue expected to improve over Q3

    80% confidence
  • D-Wave shows versatility once thought limited to gate-based systems

    80% confidence
  • Advantage system with 5,000 qubits is the largest and most powerful quantum computer in the world

    80% confidence
  • NTT DOCOMO deployment achieved 15% reduction in network congestion, solving in 40 seconds vs 27 hours classical compute

    80% confidence
  • Work by Chinese researchers shows only quantum system factoring non-trivial numbers is D-Wave annealing

    80% confidence
  • Advantage 2 will be added to Leap cloud service sooner rather than later

    80% confidence
  • The long sought killer use case for quantum is quantum optimization, and evidence shows only annealing quantum systems will deliver speed-up on quantum optimization

    80% confidence
  • D-Wave does not sell to China or Chinese companies due to US and Canada government restrictions

    80% confidence
  • D-Wave is the only quantum computing company with commercial production deployments

    80% confidence
  • D-Wave is the only quantum company offering formal SLAs

    80% confidence
  • D-Wave's annealing systems are one of few quantum technologies used by organizations to run production use cases to gain business value

    80% confidence
  • Leap Quantum Cloud Service has achieved 99.9%+ availability over 2 years

    80% confidence
  • D-Wave aims to achieve profitability with substantially less funding than competitors

    80% confidence
  • D-Wave goal is to be the first independent public quantum company to achieve sustained profitability

    80% confidence
  • Q4 bookings expected to improve over Q3

    80% confidence
  • Production apps generate high $100Ks to $1M+ annual recurring QCaaS revenue

    80% confidence
  • Go-to-market hiring expected to complete by mid-Q1 2025

    80% confidence
  • Europe is ahead of US in likely government quantum deployments

    80% confidence
  • FY2024 adjusted EBITDA loss will be less than $54.3M

    80% confidence

Data points we hold from this source

D-Wave Quantum Inc. · gross margin gaap55.8 percent
D-Wave Quantum Inc. · gross margin non gaap67.2 percent
D-Wave Quantum Inc. · lincoln park equity line remaining49.9 million_USD
D-Wave Quantum Inc. · bookings7.4 million_USD
D-Wave Quantum Inc. · adjusted ebitda loss13.8 million_USD
D-Wave Quantum Inc. · atm program remaining79.1 million_USD
D-Wave Quantum Inc. · eps-0.51 USD
D-Wave Quantum Inc. · cash30 million_USD
D-Wave Quantum Inc. · total customers132 customers
D-Wave Quantum Inc. · commercial customers76 customers
D-Wave Quantum Inc. · commercial revenue decrease0.2 million_USD
D-Wave Quantum Inc. · forbes global 2000 customers27 customers
D-Wave Quantum Inc. · research revenue increase0.6 million_USD
D-Wave Quantum Inc. · qcaas revenue5.1 million_USD
D-Wave Quantum Inc. · professional services revenue0.3 million_USD
D-Wave Quantum Inc. · patent count240 patents
D-Wave Quantum Inc. · debt0 million_USD
D-Wave Quantum Inc. · net loss66.7 million_USD
D-Wave Quantum Inc. · government revenue increase0.8 million_USD
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,362 source documents archived
Query this data → isubstrate.com
D-Wave Quantum (QBTS) Q3 2024 Earnings Transcript — Source | Via News | ViaNews Market